메뉴 건너뛰기




Volumn 29, Issue 16, 2015, Pages 2067-2070

Hit me with your best shot: Dolutegravir - A space in the next WHO guidelines?

Author keywords

antiretroviral treatment; dolutegravir; global HIV; guidelines

Indexed keywords

DARUNAVIR; DOLUTEGRAVIR; GENERIC DRUG; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; ORAL CONTRACEPTIVE AGENT; PROTEINASE INHIBITOR; RALTEGRAVIR; RIFAMPICIN; FUSED HETEROCYCLIC RINGS; INTEGRASE INHIBITOR;

EID: 84964910134     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000813     Document Type: Note
Times cited : (15)

References (19)
  • 2
    • 79955073198 scopus 로고    scopus 로고
    • Médecins Sans Frontières Access Campaign., [Accessed 22 April 2015]
    • Médecins Sans Frontières Access Campaign. Untangling the Web of antiretroviral price reductions: 17th edition. 2014. http://www.msfaccess.org/content/untangling-web-antiretrovir al-price-reductions17th-edition-%E2%80%93-july-2014.[Accessed 22 April 2015]
    • (2014) Untangling the Web of Antiretroviral Price Reductions: 17th Edition
  • 6
    • 84903303497 scopus 로고    scopus 로고
    • Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
    • Clotet B, Feinberg J, Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 2014; 383:2222-2231.
    • (2014) Lancet , vol.383 , pp. 2222-2231
    • Clotet, B.1    Feinberg, J.2    Lunzen, J.3    Khuong-Josses, M.A.4    Antinori, A.5    Dumitru, I.6
  • 7
    • 84874411899 scopus 로고    scopus 로고
    • Once-daily dolutegravir versus raltegravir in antiretroviral- naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, noninferiority SPRING-2 study
    • Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, et al. Once-daily dolutegravir versus raltegravir in antiretroviral- naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, noninferiority SPRING-2 study. Lancet 2013; 381:735-743.
    • (2013) Lancet , vol.381 , pp. 735-743
    • Raffi, F.1    Rachlis, A.2    Stellbrink, H.J.3    Hardy, W.D.4    Torti, C.5    Orkin, C.6
  • 9
    • 84897975407 scopus 로고    scopus 로고
    • Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors
    • Oliveira M, Mesplede T, Ouashie PL, Moisi D, Wainberg MA. Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors. AIDS 2014; 28:813-819.
    • (2014) AIDS , vol.28 , pp. 813-819
    • Oliveira, M.1    Mesplede, T.2    Ouashie, P.L.3    Moisi, D.4    Wainberg, M.A.5
  • 10
    • 80053293363 scopus 로고    scopus 로고
    • HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: A multicentre observational study
    • Hamers R, Wallis C, Kityo C, Siwale M, Mandaliya K, Conradie F, et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 2011; 11:750-759.
    • (2011) Lancet Infect Dis , vol.11 , pp. 750-759
    • Hamers, R.1    Wallis, C.2    Kityo, C.3    Siwale, M.4    Mandaliya, K.5    Conradie, F.6
  • 14
    • 84931025652 scopus 로고    scopus 로고
    • Dolutegravir has no effect on the pharmacokinetics of oral contraceptives with norgestimate and ethinyl estradiol
    • Song IH, Borland J, Chen S, Wajima T, Peppercorn AF, Piscitelli SC. Dolutegravir has no effect on the pharmacokinetics of oral contraceptives with norgestimate and ethinyl estradiol. Ann Pharmacother 2015; 49:784-789.
    • (2015) Ann Pharmacother , vol.49 , pp. 784-789
    • Song, I.H.1    Borland, J.2    Chen, S.3    Wajima, T.4    Peppercorn, A.F.5    Piscitelli, S.C.6
  • 15
    • 84878991956 scopus 로고    scopus 로고
    • Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): A randomised, openlabel, noninferiority study
    • SECOND LINE study group. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, openlabel, noninferiority study. Lancet 2013; 381:2091-2099.
    • (2013) Lancet , vol.381 , pp. 2091-2099
  • 16
    • 84904253549 scopus 로고    scopus 로고
    • Assessment of second-line antiretroviral regimens for HIV therapy in Africa
    • Paton N, Kityo C, Hoppe A, Reid A, Kambugu A, Lugemwa A, et al. Assessment of second-line antiretroviral regimens for HIV therapy in Africa. N Engl J Med 2014; 371:234-247.
    • (2014) N Engl J Med , vol.371 , pp. 234-247
    • Paton, N.1    Kityo, C.2    Hoppe, A.3    Reid, A.4    Kambugu, A.5    Lugemwa, A.6
  • 17
    • 79955073198 scopus 로고    scopus 로고
    • Médecins Sans Frontières Access Campaign. [Accessed 22 April 2015]
    • Médecins Sans Frontières Access Campaign. Untangling the Web of antiretroviral price reductions: 16th edition. 2013. http://www.msfaccess.org/content/untangling-web-antiretroviralprice- reductions-16th-edition. [Accessed 22 April 2015]
    • (2013) Untangling the Web of Antiretroviral Price Reductions: 16th Edition
  • 19
    • 84879874721 scopus 로고    scopus 로고
    • Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose- ranging study
    • Stellbrink HJ, Reynes J, Lazzarin A, Voronin E, Pulido F, Felizarta F, et al. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose- ranging study. AIDS 2013; 27:1771-1778.
    • (2013) AIDS , vol.27 , pp. 1771-1778
    • Stellbrink, H.J.1    Reynes, J.2    Lazzarin, A.3    Voronin, E.4    Pulido, F.5    Felizarta, F.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.